Tennor Therapeutics Limited

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]-TNP-2092

First Posted Date: 2021-10-12

Last Posted Date: 2022-10-19

Lead Sponsor: TenNor Therapeutics Limited

Target Recruit Count: 6

Registration Number: NCT05074134

Locations: 🇺🇸
Pharmaron Clinical Pharmacology Center, Baltimore, Maryland, United States

Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty

Phase 1

Completed

Conditions: Prosthetic Joint Infection

Interventions: Drug: TNP-2092

First Posted Date: 2020-03-04

Last Posted Date: 2022-10-19

Lead Sponsor: TenNor Therapeutics Limited

Target Recruit Count: 13

Registration Number: NCT04294862

Locations: 🇺🇸
Rothman Orthopedic Institute, Philadelphia, Pennsylvania, United States

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection

Phase 2

Completed

Conditions: Skin and Subcutaneous Tissue Bacterial Infections
Gram-Positive Bacterial Infections

Interventions: Drug: TNP-2092
Drug: Vancomycin

First Posted Date: 2019-05-28

Last Posted Date: 2023-12-01

Lead Sponsor: TenNor Therapeutics Limited

Target Recruit Count: 120

Registration Number: NCT03964493

Locations: 🇺🇸
eStudy Site, San Diego, California, United States

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy